These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


137 related items for PubMed ID: 3278672

  • 1. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.
    Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, Malin JP, Fierz W, Graffenried BU, Gugerli US.
    Ann Neurol; 1988 Jan; 23(1):56-63. PubMed ID: 3278672
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.
    Ann Neurol; 1990 Jun; 27(6):591-605. PubMed ID: 2193613
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A prospective randomized trial of pretransfusion/azathioprine/prednisone versus cyclosporine/prednisone immunosuppression in cardiac transplant recipients: preliminary results.
    Barnhart GR, Hastillo A, Goldman MH, Szentpetery S, Wolfgang TC, Mohanakumar T, Katz MR, Rider S, Hanrahan J, Lower RR.
    Circulation; 1985 Sep; 72(3 Pt 2):II227-30. PubMed ID: 3896555
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].
    Lhermitte F, Marteau R, Roullet E, de Saxcé H, Loridan M.
    Rev Neurol (Paris); 1984 Sep; 140(10):553-8. PubMed ID: 6438761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis.
    Woessner R, Grauer MT, Frese A, Bethke F, Ginger T, Hans A, Treib J.
    Infection; 2006 Dec; 34(6):342-4. PubMed ID: 17180590
    [Abstract] [Full Text] [Related]

  • 18. Cyclosporine and multiple sclerosis: the cons.
    Rudge P.
    Neurology; 1988 Jul; 38(7 Suppl 2):29-30. PubMed ID: 3290712
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.